ResMed reported fourth-quarter fiscal 2026 revenue of $1.5 billion, up 9% year over year, with non-GAAP earnings per share rising 16% to $2.95. For the full fiscal year ended June 30, 2026, revenue grew 10% and free cash flow topped $1.6 billion. The company also issued fiscal 2027 guidance calling for reported EPS growth of 7% to 10%, and announced a 10% dividend increase to $0.66 per share. However, life support device revenue fell 45% in the Americas and 38% elsewhere after ResMed suspended new Astral ventilator sales under a field safety action, booking a $42 million provision and expecting a roughly $75 million revenue hit in fiscal 2027. Free cash flow fell 21% to $404 million, and the pending MatrixCare divestiture is expected to dilute EPS by about $0.30.
ResMed IncRevenue growth, EPS beat, guidance, and dividend increase are positive financial results.
